TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Calliditas Therapeutics AB
Closing information (x1000 DKK)
| Closing information | 2025/03 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Turnover |
1,347,209
|
810,636
|
536,510 |
| Financial expenses |
368,114
|
76,805
|
25,172 |
| Earnings before taxes |
-432,848
|
-306,967
|
-273,586 |
| EBITDA |
-90,507
|
-239,426
|
-273,327 |
| Total assets |
1,653,406
|
1,248,807
|
1,305,041 |
| Current assets |
812,232
|
856,487
|
943,682 |
| Current liabilities |
486,399
|
273,468
|
217,329 |
| Equity capital |
111,383
|
224,881
|
512,042 |
| - share capital |
1,649
|
1,601
|
1,592 |
| Employees (average) |
62
|
181
|
86 |
Financial ratios
| Fiscal year | 2025/03 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Solvency |
6.7%
|
18.0%
|
39.2% |
| Turnover per employee |
21,729
|
4,479
|
6,238 |
| Profit as a percentage of turnover |
-32.1%
|
-37.9%
|
-51.0% |
| Return on assets (ROA) |
-3.9%
|
-18.4%
|
-19.0% |
| Current ratio |
167.0%
|
313.2%
|
434.2% |
| Return on equity (ROE) |
-388.6%
|
-136.5%
|
-53.4% |
| Change turnover | |||
| Change turnover % |
50%
|
250% | |
| Chg. No. of employees | |||
| Chg. No. of employees % |
110%
|
54% |
Total value of public sale
| Fiscal year | 2025/03 | 2023/12 (consolidated) | 2022/12 (consolidated) |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.